4D Biomaterials

Executive Summary

4D Biomaterials (4D Medicine) is a UK-based medtech company pioneering bioabsorbable polymers for surgical implants. Its proprietary 4Degra® platform enables tunable degradation rates and mechanical properties, addressing a $6 billion global market for resorbable medical devices. The company focuses on applications in orthopedics, wound closure, and drug delivery, offering advantages over permanent implants. Founded in 2016 and privately held, 4D Biomaterials has progressed from lab-scale validation to commercial-scale production, with a CE-marked product portfolio and pipeline candidates under development. With the rising demand for minimally invasive and biodegradable solutions, the company is well-positioned to capture market share, though it faces competition from established players like Ethicon and Stryker.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for a flagship 4Degra-based implant60% success
• Q4 2026Announcement of a strategic partnership or distribution agreement with a major medtech company50% success
• Q2 2026Publication of pivotal clinical trial results for 4Degra in orthopedic fixation45% success